OurCongressPublic Data • Non-Partisan
Built to help voters quickly verify how officials vote — district first, party second. All information is sourced from official public records.
← Back to bills
HR. 1620 · 119th Congress

Finn Sawyer Access to Cancer Testing Act

In committee

This bill has not become law. Status shown reflects the latest official action.

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Set my district

Bill details

Introduced: 2/26/2025
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill ID: 119hr1620
Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary

Introduced in House

Finn Sawyer Access to Cancer Testing Act This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer. Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.

Source: BILLSUM · Summary date: 2/26/2025

District impact notes

1 notes
NEUTRAL
3/27/2026

The Finn Sawyer Access to Cancer Testing Act aims to ensure coverage for certain cancer diagnostic tests under Medicare, Medicaid, and CHIP. • This legislation could improve access to advanced cancer testing for patients in the district. • Local healthcare providers may need to adapt to new guidelines and education programs related to genomic testing. • There may be questions about how the implementation of these coverage requirements will be managed and funded. AI-generated from official bill summary and plain-English note; verify with official text.

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. (No interpretation.)

Summary source label: BILLSUM
Congress.gov bill →GovInfo bill text (BILLS) →GovInfo summaries (BILLSUM) →OurCongress methodology →
About this data
  • OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
  • Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
  • District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
  • This page updates automatically via a daily ingestion pipeline.

About this data

Non-partisan by design
OurCongress provides plain-English context without endorsements, political interpretation, or advocacy.
Official sources
Data is sourced from official government records (e.g., Congress.gov, GovInfo, Clerk of the House, and the U.S. Senate).
AI-generated text
Some sections may be AI-generated from official summaries/metadata to help readability. AI output can be imperfect—verify with primary sources.
Last updated: 3/27/2026Source: BILLSUMBill: 119hr1620Learn more →